Overview
The purpose of this study is to evaluate if peri-operative zolpidem for posterior lumbar spinal fusion improves patient reported outcomes following surgery.
Description
Patients who are undergoing one- to three-level spinal fusion for degenerative lumbar disease will be recruited. They will be randomized to either receive zolpidem or placebo two days preoperatively and five days postoperatively.
Eligibility
Inclusion Criteria:
- degenerative lumbar disease
- age of 18-75
- undergoing open primary one- to three-level lumbar fusion
Exclusion Criteria:
- currently use a sleep aid nightly
- diagnosed with insomnia or sleep apnea
- history of delirium with opiates or zolpidem
- allergic to opiates or zolpidem
- had previous lumbar spine surgery
- undergoing minimally invasive lumbar fusion,
- undergoing lumbar fusion for fracture, infection, tumor, or an inflammatory spondyloarthropathy